Drugs / ScTIL
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05730361 | Feb 2023 → May 2024 | digestive system cancer | Peking University | Unknown | No outcome recorded |
| Phase 1 | NCT05499715 | Sep 2022 → May 2024 | — | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04571892 | Oct 2020 → Dec 2023 | cancer | Shanghai East Hospital | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05342506 | Apr 2022 → Feb 2024 | cervical cancer, ovarian cancer, trophoblastic neoplasm | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ScTIL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05730361 ↗ |
| Known as | Super circulating tumor infiltrating lymphocytes | “Super circulating tumor infiltrating lymphocytes(ScTIL)” NCT04571892 ↗ |
| Modality | Cell therapy | “Cell Therapy” NCT04571892 ↗ |
| Route | Intravenous | “used for one-time intravenous infusion” NCT04571892 ↗ |